Contact Us
Drug Search Results
More Filters [+]

UCART-22

Alternative Names: ucart-22, ucart22, ucart 22, u cart 22
Latest Update: 2024-12-10
Latest Update Note: News Article

Product Description

UCART-22 is being developed by Cellectis for the treatment of patients with Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04150497?term=UCART-22&draw=2&rank=1)

Mechanisms of Action: CAR-T,CD22

Novel Mechanism: Yes

Modality: Cell Therapy

Route of Administration: N/A

FDA Designation:
Orphan Drug - Acute Leukemia|Acute Lymphoid Leukemia|Leukemia|Lymphoid Leukemia
Orphan Drug - Acute Lymphoid Leukemia *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Cellectis
Company Location: PARIS, LLE-DE-FRANCE I0 75013
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for UCART-22

Countries in Clinic: France, Italy, Spain, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Acute Lymphoid Leukemia|B-Cell Leukemia|Leukemia|Lymphoma, B-Cell|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
BALLI-01

P2

Active, not recruiting

Leukemia

2040-08-08

2022-502305-15-00

P2

Unknown Status

Acute Lymphoid Leukemia|B-Cell Leukemia

2039-01-12

BALLI-01

P2

Recruiting

B-Cell Leukemia|Acute Lymphoid Leukemia|Lymphoma, B-Cell|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma

2026-01-31

Recent News Events

Date

Type

Title

12/10/2024

News Article

 Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)

08/01/2024

News Article

 FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL Treatment

07/25/2024

News Article

 FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment

06/04/2024

News Article

 Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions